National Institute of General Medical Sciences; Notice of Closed Meeting, 10038-10039 [2011-4015]
Download as PDF
<![CDATA[
10038
Federal Register / Vol. 76, No. 36 / Wednesday, February 23, 2011 / Notices
Seleda Perryman,
Office of the Secretary, HHS PRA Reports
Clearance Officer.
[FR Doc. 2011–3961 Filed 2–22–11; 8:45 am]
BILLING CODE 4151–AE–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Determination That a Demonstration
Needle Exchange Program Would be
Effective in Reducing Drug Abuse and
the Risk of Acquired Immune
Deficiency Syndrome Infection Among
Intravenous Drug Users
Office of the Secretary,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
The Surgeon General of the
United States Public Health Service,
VADM Regina Benjamin, M.D., M.B.A.,
has determined that a demonstration
needle exchange program (or more
appropriately called syringe services
program or SSP) would be effective in
reducing drug abuse and the risk of
infection with the etiologic agent for
acquired immune deficiency syndrome.
This determination reflects the scientific
evidence supporting the important
public health benefit of SSPs, and is
necessary to meet the statutory
requirement permitting the expenditure
of Substance Abuse Prevention and
Treatment (SAPT) Block Grant funds for
SSPs.
FOR FURTHER INFORMATION CONTACT:
Substance Abuse and Mental Health
Services Administration (SAMHSA), 1
Choke Cherry Road, Rockville,
Maryland, attention John Campbell,
240–276–2891.
SUPPLEMENTARY INFORMATION: The U.S.
Department of Health and Human
Services’ Substance Abuse and Mental
Health Services Administration
administers the SAPT Block Grant
authorized in section 1921 of Title XIX,
Part B, Subpart II of the Public Health
Service (PHS) Act (42 U.S.C. 300x–21).
Section 1931(a)(1)(F) of Title XIX, Part
B, Subpart II of the PHS Act (42 U.S.C.
300x–31(a)(1)(F)) prohibits the
expenditure of SAPT Block Grant funds
to ‘‘* * * carry out any program
prohibited by section 256(b) of the
Health Omnibus Programs Extension
Act of 1988’’ (42 U.S.C. 300ee–5).
Section 256(b) prohibits the use of
‘‘* * * funds provided under this Act or
an amendment made by this Act…to
provide individuals with hypodermic
needles or syringes * * * unless the
Surgeon General of the Public Health
Service determines that a demonstration
mstockstill on DSKH9S0YB1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
18:50 Feb 22, 2011
Jkt 223001
needle exchange program would be
effective in reducing drug abuse and the
risk that the public will become infected
with the etiologic agent for acquired
immune deficiency syndrome.’’
SSPs are widely considered to be an
effective way of reducing HIV
transmission among individuals who
inject illicit drugs and there is ample
evidence that SSPs also promote entry
and retention into treatment (Hagan,
McGough, Thiede, et al., 2000, Journal
of Substance Abuse Treatment, 19, 247–
252). According to research that tracks
individuals in treatment over extended
periods of time, most people who get
into and remain in treatment can reduce
or stop using illegal or dangerous drugs.
In addition to promoting entry to
treatment, there are studies that
document injection reductions for drug
users who participate in SSPs. Hagan, et
al., found that, not only were new SSP
participants five times more likely to
enter drug treatment than non-SSP
participants, former SSP participants
were more likely to report significant
reduction in injection, to stop injecting
altogether, and to remain in drug
treatment. A summary of the research
on SSPs is available at https://
www.samhsa.gov/ssp.
The Surgeon General of the United
States Public Health Service has
therefore determined that a
demonstration syringe services program
would be effective in reducing drug
abuse and the risk that the public will
become infected with the etiologic agent
for acquired immune deficiency
syndrome. The Department of Health
and Human Services plans to issue
guidelines regarding implementation
requirements for SSPs based on this
determination.
Dated: February 17, 2011.
Kathleen Sebelius,
Secretary.
[FR Doc. 2011–3990 Filed 2–18–11; 4:15 pm]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Initial
Review Group, Neurological Sciences and
Disorders K.
Date: March 10–11, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Avenue, NW., Washington, DC 20037.
Contact Person: Shanta Rajaram, PhD,
Scientific Review Officer, Scientific Review
Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3208,
MSC 9529, Bethesda, MD 20892. 301–435–
6033. rajarams@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: February 16, 2011.
Anna P. Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–4014 Filed 2–22–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel, PSI Biology Meeting.
Date: March 11, 2011.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\23FEN1.SGM
23FEN1
Federal Register / Vol. 76, No. 36 / Wednesday, February 23, 2011 / Notices
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Room
3AN12B, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Margaret J. Weidman, PhD,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3AN18B, Bethesda, MD
20892, 301–594–3663,
weidmanma@nigms.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
(Catalogue of Federal Domestic
Assistance Program Nos. 93.375,
Minority Biomedical Research Support;
93.821, Cell Biology and Biophysics
Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers;
93.96, Special Minority Initiatives,
National Institutes of Health, HHS)
Dated: February 15, 2011.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2011–4015 Filed 2–22–11; 8:45 am]
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
mstockstill on DSKH9S0YB1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Research Centers in Trauma, Burn and
Perioperative Injury.
Date: March 17, 2011.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Room
3AN12B, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Brian R. Pike, PhD,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3AN18, Bethesda, MD
20892, 301–594–3907, pikbr@mail.nih.gov.
18:50 Feb 22, 2011
Jkt 223001
[FR Doc. 2011–4016 Filed 2–22–11; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
BILLING CODE 4140–01–P
VerDate Mar<15>2010
Dated: February 15, 2011.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Chronic Pelvic Pain
Clinical Study.
Date: March 28, 2011.
Time: 2:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Paul A. Rushing, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 747, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Ulcerative Colitis
Clinical Trials.
Date: March 29, 2011.
Time: 3 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications,
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
10039
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Paul A. Rushing, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 747, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Urology Clinical
Trials.
Date: March 30, 2011.
Time: 2:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications,
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Paul A. Rushing, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 747, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Hemoglobinopathies
Program Projects.
Date: April 7, 2011.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Paul A. Rushing, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 747, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: February 16, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–4018 Filed 2–22–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, March
2, 2011, 8 a.m. to March 3, 2011, 5 p.m.,
National Institutes of Health, 6701
E:\FR\FM\23FEN1.SGM
23FEN1
]]>Agencies
[Federal Register Volume 76, Number 36 (Wednesday, February 23, 2011)]
[Notices]
[Pages 10038-10039]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-4015]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of General Medical Sciences; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of General Medical
Sciences Special Emphasis Panel, PSI Biology Meeting.
Date: March 11, 2011.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
[[Page 10039]]
Place: National Institutes of Health, Natcher Building, 45
Center Drive, Room 3AN12B, Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Margaret J. Weidman, PhD, Scientific Review
Officer, Office of Scientific Review, National Institute of General
Medical Sciences, National Institutes of Health, 45 Center Drive,
Room 3AN18B, Bethesda, MD 20892, 301-594-3663,
weidmanma@nigms.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.375,
Minority Biomedical Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology, Physiology, and
Biological Chemistry Research; 93.862, Genetics and Developmental
Biology Research; 93.88, Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National Institutes of Health, HHS)
Dated: February 15, 2011.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-4015 Filed 2-22-11; 8:45 am]
BILLING CODE 4140-01-P
